Germany Plans to Allow Homegrown and Possession of Marijuana

Regulations by 2FIRSTS.ai

Nov.28.2023

Germany Plans to Allow Homegrown and Possession of Marijuana

Germany plans to legalize the cultivation and possession of a certain quantity of marijuana for adults from April 1, 2024.

On November 27th, a legislative draft obtained by the German news agency (dpa) revealed that the German government plans to allow adults to cultivate and possess a certain quantity of marijuana starting from April 1, 2024.

Starting from July 1, 2024, it will be possible for cannabis clubs to engage in collaborative cultivation and mutual supply. Adults over the age of 18 will be permitted to possess a certain amount of cannabis, and it will also be allowed to cultivate a maximum of three cannabis plants at home.

The Social Democratic Party (SPD), the Green Party, and the health spokesperson of their parliamentary group announced in Berlin: "In the negotiations, we have agreed to shift the paradigm in drug policy concerning marijuana and recognize the social reality.

The legalization of cannabis is part of a government coalition agreement involving the three aforementioned political parties. Essentially, the plan is to remove the drug from the list of prohibited substances under the Narcotics Drugs Act.

This document still requires approval from the German parliament.

References:

[1] Alemania prevé legalizar el cultivo doméstico y la posesión de cannabis a partir del 1 de abril de 2024

Also Read:

[1] Unregulated Growth of Thailand's Recreational Cannabis Industry and Regulatory Concerns

[2] Argentina Holds 14th National Cannabis March To Protest Criminalization

[3] Colombian Justice Minister Calls for Legalization of Marijuana

#Alemania #Medical marijuana dispensary #Marijuana Vaping Products

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency

The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.

Dec.02 by 2FIRSTS.ai

South Korea’s Tobacco Law Amendment to Include Synthetic Nicotine, Projected to Add Up to $340 Million in Local Tax Revenue

Following the National Assembly’s approval of amendments to the Tobacco Business Act on September 22, redefining tobacco to include synthetic nicotine, the Korea Institute of Local Finance (KILF) estimates that local governments could gain between $37 million and $340 million in additional tax revenue in 2025 from tobacco consumption and local education taxes.

Nov.19 by 2FIRSTS.ai

Alan Zhao: China’s High-Level Crackdown on Illicit Tobacco and Vaping Will Reshape the Global Market

Alan Zhao wrote an article interpreting China's highest-level law enforcement action against illegal tobacco and e-cigarettes. He believes that this is not only an upgrade of domestic governance but will also have a profound impact on the global new tobacco supply chain and market pattern.

Dec.19 by 2Firsts Perspectives

PMI Extends Ferrari Partnership to 2026, Bringing ZYN Nicotine Pouches to F1

Philip Morris International (PMI) has announced that it will extend its partnerships with Scuderia Ferrari HP and the Ferrari Challenge through the 2026 season and beyond, with its smoke-free nicotine pouch brand ZYN set to appear on Ferrari’s F1 livery for the first time from the 2025 Abu Dhabi Grand Prix. The company estimates that, as of June 30, 2025, more than 41 million adult consumers were using its smoke-free products worldwide.